Filling the Immunological Gap

Rosenthal, Kenneth L.; Jeyanathan, Mangalakumari; Xing, Zhou

doi:10.1016/b978-0-12-415847-4.00066-5

Cited by 4 publications

(1 citation statement)

References 115 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While both intranasal and intramuscular routes induced comparable systemic humoral and T cell responses, on SARS-CoV-2 viral challenge, the hamsters vaccinated by intranasal route showed significantly lower viral loads in the nasal tract and lungs than the hamsters that received intramuscular vaccination [11]. Although recombinant human adenoviruses are the predominantly used viral vaccine vectors [150], several other recombinant viruses such as modified vaccinia virus Ankara (MVA-poxvirus) [151], chimpanzee-derived adenoviruses (ChAd) [11][12][13], recombinant rhesus cytomegalovirus (RhCMV) [152], recombinant RSV [153], recombinant lentivirus [154], attenuated influenza or parainfluenza viruses [155,156], and Newcastle disease virus (NDV) [157] have been tested with varying success as viral vectors for mucosal vaccine delivery [5].…”

Section: Live Attenuated Viruses and Viral Vectors For Mucosal Vaccinesmentioning

confidence: 98%

Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens

Dotiwala,

Upadhyay

2023

Vaccines

View full text Add to dashboard Cite

Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has the potential to prevent the infection from getting established. This is different from systemic vaccination, which protects against the development of systemic symptoms. The field of mucosal vaccination has seen fewer technological advances compared to nucleic acid and subunit vaccine advances for injectable vaccine platforms. The advent of the next-generation adenoviral vectors has given a boost to mucosal vaccine research. Basic research into the mechanisms regulating innate and adaptive mucosal immunity and the discovery of effective and safe mucosal vaccine adjuvants will continue to improve mucosal vaccine design. The results from clinical trials of inhaled COVID-19 vaccines demonstrate their ability to induce the proliferation of cytotoxic T cells and the production of secreted IgA and IgG antibodies locally, unlike intramuscular vaccinations. However, these mucosal vaccines induce systemic immune responses at par with systemic vaccinations. This review summarizes the function of the respiratory mucosa-associated lymphoid tissue and the advantages that the adenoviral vectors provide as inhaled vaccine platforms.

show abstract